精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00858 精优药业

未开盘 09-21 16:08:34

0.083

-0.001

-1.19%

最高0.084	最低0.083	成交量22.00万
今开0.084	昨收0.084	日振幅1.19%
总市值2.41亿	流通市值2.41亿	总股本29.00亿
成交额1.85万	换手率0.01%	流通股本29.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00858","market":"HK","secType":"STK","nameCN":"精优药业","latestPrice":0.083,"timestamp":1789978114395,"preClose":0.084,"halted":0,"volume":220000,"delay":0,"changeRate":-0.011904761904761915,"floatShares":2900000000,"shares":2900000000,"eps":-0.3952,"marketStatus":"未开盘","change":-0.001,"latestTime":"09-21 16:08:34","open":0.084,"high":0.084,"low":0.083,"amount":18470,"amplitude":0.011905,"askPrice":0.083,"askSize":80000,"bidPrice":0.08,"bidSize":420000,"shortable":0,"etf":0,"ttmEps":-0.338,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":0,"adr":0,"listingDate":920995200000,"exchange":"SEHK","adjPreClose":0.084,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":0.036606,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00858","defaultTab":"news","newsList":[{"id":"1186263411","title":"精优药业：Biowindow Gene Development (Hong Kong) Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186263411","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186263411?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:41","pubTimestamp":1789638067,"startTime":"0","endTime":"0","summary":"Biowindow Gene Development (Hong Kong) Limited于2026年9月16日以每股均价不详方式场外出售精优药业（00858）3.50亿股普通股，代价性质为现金。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。Biowindow Gene Development (Hong Kong) Limited此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154686806","title":"精优药业：United Gene Group Ltd减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154686806","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154686806?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:32","pubTimestamp":1789637561,"startTime":"0","endTime":"0","summary":"United Gene Group Ltd于2026年9月16日以场外交易方式出售精优药业3.50亿股，代价性质为现金，该笔交易未经联交所公开市场撮合，不属二级市场直接买卖。United Gene Group Ltd此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131020219","title":"精优药业：Biowindow Gene Development (Hong Kong) Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131020219","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131020219?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:24","pubTimestamp":1789637072,"startTime":"0","endTime":"0","summary":"Biowindow Gene Development (Hong Kong) Limited于2026年8月16日以场外交易方式（代价性质：现金）卖出精优药业（00858）3.50亿股，该笔交易并非在联交所公开市场直接买卖。Biowindow Gene Development (Hong Kong) Limited此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199775789","title":"精优药业：United Gene Holdings Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199775789","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199775789?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:23","pubTimestamp":1789637031,"startTime":"0","endTime":"0","summary":"United Gene Holdings Limited于2026年9月16日以场外现金方式出售精优药业（00858）股份3.50亿股。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。United Gene Holdings Limited此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165164926","title":"精优药业（00858）：Ease Gold Investments Limited减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165164926","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165164926?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:15","pubTimestamp":1789636501,"startTime":"0","endTime":"0","summary":"Ease Gold Investments Limited 于2026年9月16日在场外以现金方式出售精优药业（00858）3.50亿股普通股，属场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。Ease Gold Investments Limited 此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189710644","title":"精优药业：毛裕民减持，好仓比例由37.58%降至25.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189710644","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189710644?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:14","pubTimestamp":1789636457,"startTime":"0","endTime":"0","summary":"毛裕民于2026年9月16日以场外交易方式（代价性质：现金）减持精优药业3.50亿股，该笔为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。毛裕民此次减持前持有精优药业好仓10.90亿股，占比37.58%；减持后持股量为7.40亿股，好仓比例降至25.51%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116902478","title":"精优药业：JNJ Investments Ltd减持，好仓比例降至18.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116902478","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116902478?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:14","pubTimestamp":1789636456,"startTime":"0","endTime":"0","summary":"JNJ Investments Ltd于2026年9月16日以场外方式卖出精优药业股份3.50亿股（代价性质：现金）。该笔为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。JNJ Investments Ltd此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为5.50亿股，好仓比例降至18.96%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141932447","title":"精优药业：黄振平减持，好仓比例降至0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141932447","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141932447?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:24","pubTimestamp":1788945854,"startTime":"0","endTime":"0","summary":"黄振平于2026年9月8日减持精优药业股份1.00亿股。黄振平此次减持前持有精优药业好仓1.10亿股，占比3.78%；减持后持股量为970.00万股，好仓比例降至0.33%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163944921","title":"精优药业：郭懿增持，好仓比例升至3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163944921","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163944921?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:41","pubTimestamp":1788860464,"startTime":"0","endTime":"0","summary":"郭懿于2026年9月3日增持精优药业股份7000.00万股。郭懿此次增持前持有精优药业好仓2550.00万股，占比0.88%；增持后持股量为9550.00万股，好仓比例升至3.29%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114422186","title":"精优药业发布8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1114422186","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114422186?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:42","pubTimestamp":1788511353,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年9月4日公布截至2026年8月31日的股份变动月报表。公告显示，公司法定/注册股本为20,000,000,000股，面值每股HKD0.01，合计注册股本HKD200,000,000，截至报告期末保持不变。报告期内，公司已发行普通股总数为2,900,000,000股，与上月底持平，未发生新增发行、回购或注销活动。公司发行的2033年到期零息可换股债券余额为HKD352,715,000，报告期内无新的可换股债券发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662065701","title":"精优药业(00858)：楼屹退任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662065701","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662065701?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:40","pubTimestamp":1787910045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业(00858)发布公告，楼屹博士(楼博士)将于股东周年大会上轮值退任为执行董事。由于年龄及健康因素考量，楼博士已表示不会于股东周年大会上寻求连任。因此，楼博士自股东周年大会结束起退任执行董事(退任)。于彼退任后，楼博士将仍担任本公司若干附属公司的董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186549617","title":"精优药业（00858）公布最新董事及委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1186549617","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186549617?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:36","pubTimestamp":1787909804,"startTime":"0","endTime":"0","summary":"2026年8月28日，精优药业控股有限公司发布公告，更新董事会及其辖下委员会成员名单。公告显示，本次披露仅为识别用途，旨在向市场及时通报公司董事会及委员会最新构成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112810219","title":"精优药业(00858)年度股东大会全票通过6项普通决议 楼屹博士因个人原因退任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1112810219","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112810219?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:26","pubTimestamp":1787909219,"startTime":"0","endTime":"0","summary":"精优药业8月29日公告披露，公司于2026年8月28日召开股东周年大会，现场及电子出席股东就全部6项普通决议案进行投票表决，结果均获100%赞成通过，未有反对票。公司同时宣布，自股东周年大会结束起，执行董事楼屹博士因年龄及健康因素轮值退任。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115837154","title":"精优药业：Starcoin Foundation减持，好仓比例降至0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115837154","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115837154?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:12","pubTimestamp":1786698776,"startTime":"0","endTime":"0","summary":"Starcoin Foundation于2026年8月11日减持所持全部精优药业股份，持股量降至0%。Starcoin Foundation此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为0股，好仓比例降至0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199664560","title":"精优药业：仰融减持，好仓比例降至0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199664560","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199664560?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:12","pubTimestamp":1786698735,"startTime":"0","endTime":"0","summary":"仰融于2026年8月11日完成出售精优药业股份，持股量降至5%以下。仰融此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为0，好仓比例降至0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121642924","title":"精优药业2026年7月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1121642924","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121642924?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:57","pubTimestamp":1785747473,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年8月3日发布了截至2026年7月31日的证券变动月报。公告显示，公司当月未发生新增股份发行、购回或注销事项，整体股本结构与上月相比保持不变。根据公告，公司截至7月底的法定股本为200,000,000港元，分为20,000,000,000股普通股，每股面值0.01港元；上月及本月底法定股本额度一致，未发生增减变动。公告由执行董事及公司秘书王秀娟签署，精优药业再次强调将持续遵守香港联交所《上市规则》及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117742241","title":"精优药业（00858）公布将自2026年8月3日起更改百慕达注册办事处及股份过户登记总处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1117742241","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117742241?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:35","pubTimestamp":1785486928,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司（00858）7月31日公告称，公司董事会决定自2026年8月3日起，更改其在百慕达的注册办事处及股份过户登记总处地址，新的地址为：Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda。\n公告同时确认，公司于香港的股份过户登记分处仍为卓佳证券登记有限公司，相关股份过户登记事宜应继续递交至香港夏悫道16号远东金融中心17楼的卓佳证券登记有限公司。\n截至公告日，公司执行董事包括谢毅博士、郭懿博士、程勇先生、楼屹博士及王秀娟女士，独立非执行董事为金松女士、曾立博士及杨晓蓉女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103564275","title":"精优药业2026财年由盈转亏，全年录得9.797亿港元亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1103564275","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103564275?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:45","pubTimestamp":1785401153,"startTime":"0","endTime":"0","summary":"精优药业于百慕大注册，在香港联合交易所有限公司上市。公司主要从事医药制造与分销等业务，涵盖自有品牌药物的研发与生产，并通过可转换债券等财务投资进行协同管理。公司董事会由执行董事及独立非执行董事组成，下设审核委员会、薪酬委员会及提名委员会，分别负责审计、薪酬和提名等事宜。在截至2026年3月31日止的报告期内，公司财务业绩出现明显下滑，归属于公司所有者的亏损约为9.797亿港元，而上一财年则录得约2.23亿港元的盈利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"精优药业2026财年由盈转亏，全年录得9.797亿港元亏损","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134927894","title":"精优药业(00858)计划于2026年8月28日召开年度股东大会 将审议发行及回购股份等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1134927894","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134927894?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:41","pubTimestamp":1785400911,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司7月31日发布公告称，公司已定于2026年8月28日上午11时在香港铜锣湾怡和街88号富豪香港酒店低座二楼聚贤会议厅及聚贤厅II召开股东周年大会，审议公司截至2026年3月31日止年度的多项事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121876598","title":"精优药业拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1121876598","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121876598?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:37","pubTimestamp":1785400636,"startTime":"0","endTime":"0","summary":"精优药业公告称，董事会已议决在股东大会上提呈一项回购股份授权方案，允许公司于香港联合交易所有限公司或其他获认可证券交易所回购最高不超过已发行股份总数10%的股份。基于公司已发行2,900,000,000股股份，此次回购上限约2.90亿股。董事会认为，适时回购股份有助于提升每股资产净值和每股盈利水平，符合公司和股东的整体最佳利益。公告显示，过去一年，精优药业于港股市场的最高成交价为每股0.149港元，最低为每股0.054港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"精优药业拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.extrawell.com.hk","stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0375},{"period":"3month","weight":0.2388},{"period":"6month","weight":0.0641},{"period":"1year","weight":-0.2845},{"period":"ytd","weight":0.0122}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.0372},{"period":"3month","weight":0.0731},{"period":"6month","weight":-0.0116},{"period":"1year","weight":-0.0566},{"period":"ytd","weight":-0.0229}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"精优药业控股有限公司是一家主要从事开发、制造及销售药品的投资控股公司。该公司主要通过三个分部运营业务。制造分部从事医药产品的开发、制造及销售业务。其自制产品包括转移因子口服溶液、贯新克及洲邦等。贸易分部从事进口药品的推广及经销业务。其进口产品包括美利巴及适今可。基因开发分部从事基因相关技术的商业开发及研发业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.407407,"avgChangeRate":0.054952},{"month":2,"riseRate":0.518519,"avgChangeRate":0.035392},{"month":3,"riseRate":0.296296,"avgChangeRate":0.026028},{"month":4,"riseRate":0.321429,"avgChangeRate":0.010323},{"month":5,"riseRate":0.392857,"avgChangeRate":0.096347},{"month":6,"riseRate":0.392857,"avgChangeRate":0.057621},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039625},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.034399},{"month":9,"riseRate":0.357143,"avgChangeRate":-0.021423},{"month":10,"riseRate":0.333333,"avgChangeRate":0.010027},{"month":11,"riseRate":0.423077,"avgChangeRate":0.02567},{"month":12,"riseRate":0.296296,"avgChangeRate":-0.022304}],"exchange":"SEHK","name":"精优药业","nameEN":"EXTRAWELL PHAR"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供精优药业(00858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"精优药业,00858,精优药业股票,精优药业股票老虎,精优药业股票老虎国际,精优药业行情,精优药业股票行情,精优药业股价,精优药业股市,精优药业股票价格,精优药业股票交易,精优药业股票购买,精优药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供精优药业(00858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}